Andy Walker, CEO of Jewel Therapeutics
Our second keynote speaker is Andy Walker, CEO of Jewel Therapeutics and formerly Senior Vice President of Technical Operations at Juno Therapeutics. He has a prolific resume working with #biotech startups and will be speaking about #entrepreneurship in the industry!
Andy is an experienced senior leader overseeing Process Development and GMP manufacturing of cellular therapeutics and protein biologics. He is the former Senior Vice President of Technical Operations at Juno Therapeutics where he led Process and Analytical Development, CMC Lifecycle Management and GMP Manufacturing departments. He oversaw the growth of the Technical Operations organization from less than 10 people to more than 200 people and supported the Juno IPO and business development due diligence activities. Andy oversaw all aspects of the development of production processes for Juno cell therapy products and was responsible for establishing the GMP supply strategy for autologous CAR-T and TCR products. He also led all aspects of site selection, design, construction, start-up and operation of the Juno Manufacturing Plant (JuMP), an innovative, multi-product GMP manufacturing facility designed for global clinical and commercial supply of CAR-T and TCR cell therapies.
Prior to joining Juno, Andy served in multiple senior leadership roles at CMC Biologics, a contract biologics drug development and manufacturing organization. While at CMC Biologics, Andy’s senior management roles included serving as the head of the GMP Manufacturing Department, where he led the design, start-up and operation of multiple GMP manufacturing facilities. Andy also served as the head of the Process Development organization where he oversaw all aspects of drug development from cell line creation, upstream and downstream process development, analytical and formulation development, and process transfer and process validation. Andy is currently serving as the CEO of Jewel Biotherapeutics, a start-up company currently raising funds to support the development of novel cell therapies using technology from the UW and Seattle Children’s.